ICD-10 Code R97.20: Elevated PSA Levels (Prostate-Specific Antigen)

Key Takeaways

R97.20 codes elevated PSA as an abnormal finding, not a confirmed diagnosis

Documentation must include the specific PSA value and clinical context

Do not use R97.20 if prostate cancer is confirmed-use C61 instead

Medicare covers annual PSA screening for men over 50 under specific conditions

Pair R97.20 with CPT 84153 or 84154 for complete billing documentation

Introduction to ICD-10 Code R97.20

ICD-10 code R97.20 represents elevated prostate-specific antigen (PSA) levels documented as an abnormal finding without a confirmed diagnosis of prostate cancer. This diagnostic code sits within Chapter XVIII (Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified) of the WHO ICD-10 classification system, specifically under category R97 (Abnormal tumor markers).

Healthcare providers use this code when PSA test results exceed normal reference ranges, but clinical evaluation has not yet established a definitive diagnosis. The code applies across multiple care settings-primary care offices, urology practices, and oncology centers-whenever documentation reflects an abnormal PSA result requiring further investigation. Proper use of R97.20 ensures accurate medical records, supports appropriate follow-up pathways, and meets payer requirements for subsequent diagnostic procedures.

What is ICD-10 Code R97.20?

R97.20 identifies elevated prostate-specific antigen levels as an abnormal laboratory finding. The code does not indicate the presence of disease. It reflects a test result that falls outside established reference ranges, prompting clinical concern but requiring additional workup before any diagnosis can be assigned. According to CMS ICD-10-CM guidelines, codes from the R00-R99 range describe symptoms, signs, and abnormal findings-not confirmed conditions.

PSA is a glycoprotein produced by both normal and malignant prostate tissue. Elevated levels may result from benign prostatic hyperplasia, prostatitis, urinary tract infection, recent sexual activity, or malignancy. The R97.20 code captures the objective finding without attributing causation. Clinicians document this code when the PSA value exceeds the lab’s reference range-typically above 4.0 ng/mL, though thresholds vary by patient age and risk profile-and when the clinical picture does not yet support a more specific diagnosis.

This distinction matters for claims processing. Payers review documentation to verify medical necessity for follow-up tests such as repeat PSA measurements, free PSA ratio calculations, or prostate biopsies. Using R97.20 appropriately signals that the abnormal finding justifies subsequent evaluation without overstating diagnostic certainty. For practices managing claims workflows, accurate code assignment reduces denial rates and supports timely reimbursement.

ICD-10 Code R97.20: Clinical Documentation Requirements

Documentation must specify the PSA value, the lab reference range, and the clinical context surrounding the test. Generic statements such as “elevated PSA” do not meet coding standards. The medical record should include the numeric result (e.g., “PSA 6.8 ng/mL, reference range 0-4.0 ng/mL”), the date of testing, and any relevant patient history-prior PSA trends, current medications (particularly 5-alpha reductase inhibitors), recent prostate manipulation, or symptoms prompting the test.

Medicare and commercial payers expect documentation that supports medical necessity for both the initial PSA test and any follow-up procedures. For practices using digital intake forms, structured data fields for PSA values and clinical notes streamline this process. The Centers for Medicare & Medicaid Services requires that claims for PSA screening or diagnostic testing include appropriate diagnosis codes justifying the service. R97.20 satisfies this requirement when the test result itself is the finding under investigation.

The record should also note whether the elevated PSA represents an initial finding or a repeat test following a prior abnormal result. Repeat testing within a short interval may require additional justification, particularly under Medicare coverage policies that limit screening frequency. Documentation should reflect the provider’s clinical reasoning-why the test was ordered, what the result indicates, and what follow-up is planned. This narrative supports both coding accuracy and audit defense.

Key Documentation Elements for R97.20

• Exact PSA value in ng/mL
• Laboratory reference range
• Date of test collection
• Patient age and relevant medical history
• Prior PSA results (if available)
• Clinical context: screening vs. diagnostic indication
• Plan for follow-up or additional testing

R97.20 Code Comparison Chart

Understanding when to use R97.20 versus related diagnostic codes prevents coding errors and claim denials. The table below compares R97.20 with commonly confused codes in prostate health documentation.

R97.20 vs. C61 (Prostate Cancer)

Never use R97.20 if prostate cancer has been confirmed through biopsy or imaging. Once pathology establishes malignancy, the definitive diagnosis code C61 supersedes the abnormal finding code. Sequencing rules require the most specific code available. Continuing to use R97.20 after cancer confirmation constitutes improper coding and may trigger payer audits. The clinical record must clearly document the transition from abnormal finding to confirmed diagnosis, with the corresponding code change reflected in all subsequent claims.

R97.20 vs. Z12.5 (Screening)

Z12.5 applies when a patient presents for routine prostate cancer screening without symptoms or prior abnormal results. Use this code when ordering the PSA test as a preventive service. Once the result returns elevated, subsequent encounters addressing that abnormal finding should use R97.20. The distinction affects reimbursement-Medicare covers annual PSA screening under Z12.5 but may require different authorization for diagnostic follow-up coded with R97.20. Practices managing men’s health clinics must track this sequencing to ensure correct claim submission.

Related Codes to ICD-10 R97.20

Several ICD-10 codes commonly appear alongside R97.20 in urology and primary care documentation. Understanding these relationships helps clinicians select the most appropriate code for each encounter. When a patient has multiple conditions affecting the prostate, assign all applicable codes, but sequence them according to the reason for the visit.

N40 Series: Benign Prostatic Hyperplasia

Codes N40.0 (BPH without lower urinary tract symptoms) and N40.1 (BPH with LUTS) may coexist with R97.20. Benign prostatic enlargement elevates PSA through increased prostate tissue volume, not malignancy. When a patient has confirmed BPH and an elevated PSA, both codes apply. The principal diagnosis depends on the encounter focus-if addressing urinary symptoms, list the N40 code first; if evaluating the abnormal PSA, R97.20 takes precedence. Documentation must distinguish between PSA elevation attributable to BPH and unexplained elevation requiring cancer workup.

R97.21: Rising PSA Following Treatment

This code captures PSA elevation after prostate cancer treatment (prostatectomy, radiation, hormonal therapy). It differs from R97.20 by indicating a specific clinical context-biochemical recurrence surveillance rather than initial diagnostic workup. Use R97.21 when PSA rises in a patient with a history of treated prostate cancer. The code signals to payers that testing relates to post-treatment monitoring, which may have different coverage criteria than initial screening or diagnostic evaluation.

N42.1: Congestion and Hemorrhage of Prostate

Acute prostate inflammation from recent sexual activity, vigorous exercise, or instrumentation can temporarily elevate PSA. If documentation attributes the elevated PSA to such causes, N42.1 may apply. However, clinicians should use caution-this code requires explicit evidence of the precipitating event and should not serve as a default explanation for every mildly elevated PSA. When the cause remains uncertain, R97.20 remains the appropriate code pending further evaluation.

Streamline Your Prostate Health Workflows

Manage PSA tracking, follow-up scheduling, and coding documentation in one platform designed for urology and primary care practices.

Book a demo

Billing Codes for PSA Testing

CPT codes 84153 and 84154 describe the laboratory procedures for measuring PSA. These procedural codes pair with R97.20 on claims to represent the complete clinical picture-the test performed and the finding documented. Accurate pairing ensures payers understand both what was done and why.

CPT 84153: Total PSA

This code covers quantitative measurement of total prostate-specific antigen in serum. Most initial PSA tests use this code. When the result exceeds the reference range, the claim includes both CPT 84153 (the test) and R97.20 (the abnormal finding). Documentation should confirm that the test was medically necessary-whether for screening (paired with Z12.5 initially) or diagnostic purposes (paired with symptoms or prior abnormal results).

CPT 84154: Free PSA

Free PSA measures the unbound fraction of PSA in serum, typically ordered as a reflex test when total PSA falls in an indeterminate range (4-10 ng/mL). The free-to-total PSA ratio helps stratify prostate cancer risk-lower ratios suggest higher malignancy probability. When billing CPT 84154 following an elevated total PSA, R97.20 remains the appropriate diagnosis code, as the finding prompting the reflex test is still the abnormal PSA level. Practices using lab tracking systems should flag cases requiring reflex testing to ensure complete billing capture.

Medicare Coverage Considerations

Medicare covers annual PSA screening (CPT 84153 with Z12.5) for men over 50 under specific conditions. Once a result returns elevated, follow-up testing may fall under diagnostic rather than screening coverage. Claims for repeat PSA within the annual screening window require strong documentation justifying medical necessity-typically the prior abnormal result coded as R97.20. Local Coverage Determinations (LCDs) vary by Medicare Administrative Contractor, so practices should verify coverage policies in their jurisdiction before submitting claims.

When to Use ICD-10 Code R97.20 vs. Other Codes

Clinical decision-making determines which code applies. R97.20 fits a narrow scenario: PSA results exceed normal limits, clinical evaluation is ongoing, and no definitive diagnosis yet exists. If the provider establishes a specific cause-BPH, prostatitis, or cancer-that diagnosis code replaces R97.20 in subsequent documentation.

Consider a 62-year-old man presenting for annual screening. The initial encounter uses Z12.5. PSA returns at 6.2 ng/mL. At the follow-up visit to discuss results, R97.20 becomes the primary diagnosis, as the encounter addresses an abnormal finding. If repeat testing and digital rectal examination suggest BPH, the next visit codes N40.0 or N40.1, with R97.20 as a secondary code if the PSA elevation remains unexplained. Should biopsy confirm cancer, all subsequent encounters list C61, and R97.20 drops from the record.

Documentation must reflect this progression. Each visit note should state what is known, what remains uncertain, and what diagnostic steps are planned. This narrative supports the coding choices and demonstrates appropriate clinical reasoning to auditors. For clinics managing complex primary care patient panels, structured templates can standardize this documentation while preserving clinical nuance.

Common Coding Errors with R97.20

• Using R97.20 after cancer diagnosis is confirmed
• Failing to document the specific PSA value
• Coding routine screening as R97.20 before results are known
• Omitting clinical context that justifies repeat testing
• Not transitioning to a definitive diagnosis code when appropriate
• Sequencing R97.20 as principal diagnosis when a confirmed condition exists

Clinical Pathways Following R97.20 Documentation

An elevated PSA documented with R97.20 triggers a standardized evaluation pathway. The American Urological Association recommends shared decision-making for men aged 55-69, discussing risks and benefits of further testing. For men outside this age range or those with concerning PSA velocity (rate of rise over time), more aggressive workup may proceed without delay.

Typical next steps include repeat PSA testing after 4-6 weeks to confirm persistence, calculation of free-to-total PSA ratio, and digital rectal examination. If abnormalities persist, providers may order prostate MRI or proceed directly to transrectal ultrasound-guided biopsy. Each step generates additional documentation and coding requirements. Practices using automated care pathways can embed these decision trees into their EMR, ensuring consistent follow-up and reducing the risk of missed steps.

Patient education at this stage is critical. Many men equate elevated PSA with cancer, despite the majority of cases resulting from benign causes. Documentation should note the patient’s understanding of next steps, anxiety level, and any questions raised. This qualitative information supports both clinical decision-making and coding accuracy, as it justifies the intensity and frequency of follow-up encounters.

Age-Specific PSA Reference Ranges

Standard PSA thresholds do not account for age-related prostate growth. Age-adjusted reference ranges reduce false positives in older men while maintaining sensitivity in younger patients. While 4.0 ng/mL remains a common cutoff, many clinicians apply stricter thresholds for men under 60 and higher thresholds for men over 70. Documentation should note which reference range the lab used and whether age adjustment factored into interpretation.

Expert Picks

Need structured PSA tracking forms? Digital Forms enable custom templates for prostate health documentation, including PSA trend graphs and risk calculators.

Managing high-volume urology workflows? Appointment Scheduling automates follow-up booking based on PSA results and clinical protocols.

Want to reduce coding errors? Echo AI assists with clinical note generation, flagging coding inconsistencies before claims submission.

Conclusion

ICD-10 code R97.20 serves a specific function: documenting elevated PSA levels as an abnormal finding requiring further evaluation. Proper use depends on clear documentation of the PSA value, clinical context, and diagnostic reasoning. The code bridges initial screening and definitive diagnosis, supporting medical necessity for follow-up testing while avoiding premature assignment of disease codes.

Clinicians must distinguish R97.20 from related codes-using Z12.5 for screening encounters, C61 for confirmed cancer, and N40 series codes for benign prostatic conditions. Each clinical encounter should advance the diagnostic process, with coding choices reflecting the current state of knowledge. Accurate documentation protects both the practice and the patient, ensuring appropriate care delivery and reimbursement while maintaining compliance with payer policies and coding standards.

Frequently Asked Questions